Lippincott ® NursingCenter ® Wolters Kluwer Logo

Web-Banner-for-LNC.jpg

New Drug Indications - May 2025

cabozantinib

Cabometyx
Pharmaceutical company: Exelixis, Inc.


NEW INDICATION & DOSAGE
Previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors (Cabometyx only)
Adults and children ages 12 and older weighing 40 kg or more: 60 mg PO daily until disease progression or unacceptable toxicity.
Children ages 12 and older weighing less than 40 kg: 40 mg PO daily until disease progression or unacceptable toxicity.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

durvalumab

Imfinzi
Pharmaceutical company: AstraZeneca


NEW INDICATION & DOSAGE
Muscle-invasive bladder cancer
Adults weighing 30 kg or more: 1,500 mg IV every 3 weeks in combination with gemcitabine and cisplatin for 4 cycles prior to surgery, followed by 1,500 mg IV every 4 weeks as a single agent for up to 8 cycles after surgery.
Adults weighing less than 30 kg: 20 mg/kg IV every 3 weeks in combination with gemcitabine and cisplatin for 4 cycles prior to surgery, followed by 20 mg/kg IV every 4 weeks as a single agent for up to 8 cycles after surgery.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

eculizumab

Soliris
Pharmaceutical company: Alexion Pharmaceuticals


NEW INDICATION & DOSAGE
Generalized myasthenia gravis in patients who are anti-acetylcholine receptor antibody positive
Children ages 6 and older weighing 40 kg or more: 900 mg IV once every 7 days for 4 weeks, then 1,200 mg IV 7 days later (week 5), followed by 1,200 mg IV every 2 weeks thereafter.
Children ages 6 and older weighing 30 to less than 40 kg: 600 mg IV once every 7 days for 2 weeks, then 900 mg IV 7 days later (week 3), followed by 900 mg IV every 2 weeks thereafter.
Children ages 6 and older weighing 20 to less than 30 kg: 600 mg IV once every 7 days for 2 weeks, then 600 mg IV 7 days later (week 3), followed by 600 mg IV every 2 weeks thereafter.
Children ages 6 and older weighing 10 to less than 20 kg: 600 mg IV once every 7 days on week 1, then 300 mg IV 7 days later (week 2), followed by 300 mg IV every 2 weeks thereafter.
Children ages 6 and older weighing 5 to less than 10 kg: 300 mg IV once every 7 days on week 1, then 300 mg IV 7 days later (week 2), followed by 300 mg IV every 3 weeks thereafter.

Adjust-a-dose: Give a supplemental dose within 60 minutes after each plasmapheresis or plasma exchange session. If the most recent dose was 300 mg, give 300-mg supplemental dose. If the most recent dose was 600 mg or more, give 600-mg supplemental dose. For patients receiving fresh frozen plasma, if the most recent dose was 300 mg or more, give 300-mg supplemental dose 1 hour before each unit of fresh frozen plasma. In a patient receiving concomitant IV immunoglobulin treatment, refer to the manufacturer's instructions for supplemental eculizumab dose requirements and timing.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

emtricitabine-rilpivirine-tenofovir alafenamide

Odefsey
Pharmaceutical company: Gilead Sciences


NEW INDICATION & DOSAGE
HIV-1 infection as initial therapy in patients with no antiretroviral treatment history and HIV-1 RNA of 100,000 copies/mL or less; or to replace a stable antiretroviral regimen in patients who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components
Children ages 6 and older weighing at least 25 kg: 1 tablet PO daily with a meal.

Adjust-a-dose: For patients on hemodialysis, give 1 tablet daily; give after hemodialysis on dialysis days. This drug isn't recommended for patients with creatinine clearance of less than 30 mL/minute or in patients with chronic kidney disease who aren't receiving long-term dialysis.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

epinephrine

Neffy
Pharmaceutical company: ARS Pharma

NEW AVAILABLE FORM
Nasal spray: 1 mg/0.1 mL per single-dose spray

NEW INDICATION & DOSAGE
Type I allergic reactions, including anaphylaxis
Adults and children ages 4 and older weighing 15 to less than 30 kg: One spray (1 mg) into one nostril. If there is no clinical response or worsening symptoms, repeat the dose after 5 minutes in the same nostril.

 

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

furosemide

Furoscix
Pharmaceutical company: scPharmaceuticals


NEW INDICATION & DOSAGE
Edema in patients with chronic kidney disease, including the nephrotic syndrome
Adults: Subcutaneous on-body infusor with prefilled cartridge preprogrammed to deliver 30 mg over first hour, followed by 12.5 mg per hour for subsequent 4 hours. Total dose, 80 mg over 5 hours.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

glucagon

Baqsimi
Pharmaceutical company: Amphastar Pharmaceuticals


NEW INDICATION & DOSAGE
Severe hypoglycemia in patients with diabetes
Children ages 1 and older: 3 mg (one actuation of intranasal device) into one nostril. If there is no response after 15 minutes, the dose may be repeated.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

pembrolizumab

Keytruda
Pharmaceutical company: Merck


NEW INDICATION & DOSAGE
First-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy
Adults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in patients without disease recurrence. Give before trastuzumab and chemotherapy, when given the same day.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

tenecteplase

TNKase
Pharmaceutical company: Genentech


NEW INDICATION & DOSAGE
Acute ischemic stroke
Adults weighing 90 kg or more: 25 mg (5 mL) by IV bolus over 5 seconds.
Adults weighing 80 to less than 90 kg: 22.5 mg (4.5 mL) by IV bolus over 5 seconds.
Adults weighing 70 to less than 80 kg: 20 mg (4 mL) by IV bolus over 5 seconds.
Adults weighing 60 to less than 70 kg: 17.5 mg (3.5 mL) by IV bolus over 5 seconds.
Adults weighing less than 60 kg: 15 mg (3 mL) by IV bolus over 5 seconds.

Adjust-a-dose: Begin treatment as soon as possible and within 3 hours of the onset of stroke symptoms.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

tesamorelin acetate

Egrifta WR
Pharmaceutical company: Theratechnologies

NEW AVAILABLE FORM
Injection (Egrifta WR):11.6-mg vials

NEW INDICATION & DOSAGE
Reduction of excess abdominal fat in patients infected with HIV-1 with lipodystrophy
Adults: Inject 1.28 mg (0.16 mL) subcut once daily in abdomen.

Released: May 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

New Drug Indications Archive

New Drug Indications - May 2022
nivolumabOpdivoPharmaceutical company: Bristol-Myers SquibbNEW INDICATION & DOSAGENeoadjuvant treatment of resectable non–small-cell lung cancer (tumors of at least 4 cm or node-positive) in combination with platinum-doublet chemotherapyAdults: 360-mg IV infusion followed by platinum-doublet chemotherapy on the same day every 3 weeks for 3 cycles.Released: May 2022Nursing Drug Handbook© 2022 Wolters KluwersirolimusHyftorPharmaceutical company: Nobelpharma AmericaNEW FORMTopical gel:2 mg/gINDICATION & DOSAGEFacial angiofibroma associated with tuberous sclerosisAdults and children age 12 and older: Apply to facial skin b.i.d. Maximum dose, 800 mg (2.5 cm).Children ages 6 to 11: Apply to facial skin b.i.d. Maximum dose, 600 mg (2 cm).Adjust-a-dose: Reevaluate need for the drug if symptoms don’t improve within 12 weeks of treatment.Released: May 2022Nursing Drug Handbook© 2022 Wolters KluwerupadacitinibRinvoqPharmaceutical company: AbbVieNEW INDICATION & DOSAGEModerate to severe active ulcerative colitis after inadequate response or intolerance to one or more TNF blockersAdults: 45 mg PO once daily for 8 weeks, followed by a maintenance dose of 15 mg once daily. May increase maintenance dose to 30 mg once daily for patients with refractory, severe, or extensive disease. If patient response to 30-mg dose is inadequate, discontinue the drug. Use the lowest effective dose needed to maintain response.Adjust-a-dose: If the patient has severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2), mild to moderate hepatic impairment (Child-Pugh class A or B), or is taking a strong CYP3A4 inhibitor, give induction dose, 30 mg once daily for 8 weeks; then maintenance dose, 15 mg once daily.Released: May 2022Nursing Drug Handbook© 2022 Wolters Kluwer 
New Drug Indications - April 2022
remdesivirVekluryPharmaceutical company: Gilead Sciences, Inc.NEW INDICATION & DOSAGETreatment of non-hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19) at high risk for progression to severe COVID-19, including hospitalization or deathAdults and children age 12 and older, weighing 40 kg or more: Initiate therapy as soon as possible after diagnosis and within 7 days of symptom onset with 200-mg IV infusion on day 1, followed by 100-mg IV infusion once daily on days 2 and 3.Adjust-a-dose:Consider discontinuing the drug if ALT level increases to greater than 10 × the upper limit of normal. Discontinue if ALT elevation is accompanied by signs or symptoms of liver inflammation.Released: April 2022Nursing Drug Handbook© 2022 Wolters Kluwer  risankizumab-rzaaSkyriziPharmaceutical company: AbbVie Inc.NEW INDICATION & DOSAGEActive psoriatic arthritisAdults: 150 mg (two 75-mg injections) subcut at week 0, week 4, and every 12 weeks thereafter, alone or in combination with nonbiologic disease-modifying antirheumatic drugs.Released: April 2022Nursing Drug Handbook© 2022 Wolters Kluwer  secnidazoleSolosecPharmaceutical company: Lupin Pharmaceuticals, Inc.NEW INDICATION & DOSAGEBacterial vaginosisFemales age 12 and older: One single dose of 2 g PO.TrichomoniasisChildren age 12 and older: One single dose of 2 g PO. Treat sexual partners with same dose at same time.Released: April 2022Nursing Drug Handbook© 2022 Wolters Kluwer
New Drug Indications - March 2022
brexpiprazoleRexultiPharmaceutical company: Otsuka America PharmaceuticalsNEW INDICATION & DOSAGESchizophreniaChildren age 13 and older: Initially, 0.5 mg PO once daily on days 1 through 4; then titrate to 1 mg PO once daily on days 5 through 7; then increase to 2 mg PO once daily on day 8 based on patient's response and tolerability. Increase by 1 mg weekly, if indicated. Recommended target dose, 2 to 4 mg daily. Maximum daily dose, 4 mg.Boxed Warning: Safety and effectiveness in children with major depressive disorder haven't been established.Boxed Warning: Closely monitor all antidepressant-treated patients for worsening and emergence of suicidal thoughts and behaviors, especially during initial months of therapy and after dosage change.Released: March 2022Nursing Drug Handbook© 2022 Wolters Kluweremtricitabine and tenofovir alafenamideDescovyPharmaceutical company: Gilead SciencesNEW AVAILABLE FORMTablets: 120 mg emtricitabine and 15 mg tenofovir alafenamideNEW INDICATION & DOSAGEHIV-1 infection in combination with other antiretrovirals other than protease inhibitors that require a CYP3A inhibitorChildren weighing at least 14 to less than 25 kg with creatinine clearance of 30 mL/minute or more: One 120 mg/15 mg tablet PO once daily.Released: March 2022Nursing Drug Handbook© 2022 Wolters KluwerglycopyrrolateDartisla ODTPharmaceutical company: Edenbridge PharmaNEW AVAILABLE FORMTablets (ODT [orally disintegrating tablets]): 1.7 mgNEW INDICATION & DOSAGEAdjunct to treatment to reduce symptoms in patients with peptic ulcer Adults: 1.7 mg b.i.d. or t.i.d. Maximum daily dosage, 6.8 mg.Adjust-a-dose: Patients receiving 2-mg dose of another oral tablet form of glycopyrrolate may be switched to ODT. Use lowest effective dose to control symptoms; switch to another oral tablet form of glycopyrrolate in patients who can be titrated to lower dose.Released: March 2022Nursing Drug Handbook© 2022 Wolters KluwerlumateperoneCaplytaPharmaceutical company: Intra-Cellular TherapiesNEW INDICATION & DOSAGEDepressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy or as adjunctive therapy with lithium or valproateAdults: 42 mg PO once daily.Released: March 2022Nursing Drug Handbook© 2022 Wolters KluwerribociclibKisqaliPharmaceutical company: NovartisNEW INDICATION & DOSAGEHormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in menMen: 600 mg (three 200-mg tablets) PO once daily for 21 consecutive days followed by 7 days off therapy. When combined with fulvestrant, give 500 mg fulvestrant PO on days 1, 15, and 29, and once monthly thereafter. Refer to full prescribing information of fulvestrant. Men should also be treated with a luteinizing hormone-releasing hormone agonist, according to current clinical practice standards.Adjust-a-dose: Refer to the manufacturer's instructions for toxicity-related dosage adjustment. For patients with moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment, reduce starting dose to 400 mg once daily. For patients with severe renal impairment, reduce starting dose to 200 mg PO once daily. If use with a strong CYP3A inhibitor can't be avoided, reduce ribociclib dose to 400 mg daily; allow five half-lives of the inhibitor after discontinuation of the inhibitor before returning to the initial ribociclib dose.Released: March 2022Nursing Drug Handbook© 2022 Wolters KluwerrivaroxabanXareltoPharmaceutical company: Janssen PharmaceuticalsNEW FORMULATIONGranules for oral suspension: 1 mg/mL after reconstitutionINDICATIONS & DOSAGEVenous thromboembolism and reduction of risk of recurrent venous thromboembolism after at least 5 days of initial parenteral anticoagulant therapyChildren from birth to less than age 18, weighing 50 kg or more: 20 mg oral suspension or tablets PO daily.Children from birth to less than age 18, weighing 30 to 49.9 kg: 15 mg oral suspension or tablets PO daily.Children from birth to less than age 18, weighing 12 to 29.9 kg: 5 mg oral suspension PO b.i.d.Children from birth to less than age 18, weighing 10 to 11.9 kg: 3 mg oral suspension PO t.i.d.Children from birth to less than age 18, weighing 9 to 9.9 kg: 2.8 mg oral suspension PO t.i.d.Children from birth to less than age 18, weighing 8 to 8.9 kg: 2.4 mg oral suspension PO t.i.d.Children from birth to less than age 18, weighing 7 to 7.9 kg: 1.8 mg oral suspension PO t.i.d.Children from birth to less than age 18, weighing 5 to 6.9 kg: 1.6 mg oral suspension PO t.i.d.Children from birth to less than age 18, weighing 4 to 4.9 kg: 1.4 mg oral suspension PO t.i.d.Children from birth to less than age 18, weighing 3 to 3.9 kg: 0.9 mg oral suspension PO t.i.d.Children from birth to less than age 18, weighing 2.6 to 2.9 kg: 0.8 mg oral suspension PO t.i.d.Adjust-a-dose: Children less than 6 months should have been at least 37 weeks of gestation at birth, have had at least 10 days of oral feeding, and weigh 2.6 kg or more at the time of dosing. Continue therapy for at least 3 months and up to 12 months, when necessary. In children less than age 2 with catheter-related thrombosis, continue therapy for at least 1 month and up to 3 months, when necessary. Avoid use in children age 1 and older with moderate or severe renal impairment (eGFR less than 50 mL/min/1.73 m2). Refer to the manufacturer's instructions for renal impairment in children less than age 1 and for recommendations for switching to and from other anticoagulants.Thromboprophylaxis in patients with congenital heart disease after the Fontan procedureChildren age 2 and older, weighing 50 kg or more: 10 mg oral suspension or tablets PO daily.Children age 2 and older, weighing 30 to 49.9 kg: 7.5 mg oral suspension PO daily.Children age 2 and older, weighing 20 to 29.9 kg: 2.5 mg oral suspension PO b.i.d.Children age 2 and older, weighing 12 to 19.9 kg: 2 mg oral suspension PO b.i.d.Children age 2 and older weighing 10 to 11.9 kg: 1.7 mg oral suspension PO b.i.d.Children age 2 and older, weighing 8 to 9.9 kg: 1.6 mg oral suspension PO b.i.d.Children age 2 and older weighing 7 to 7.9 kg: 1.1 mg oral suspension PO b.i.d.Adjust-a-dose: Avoid use in children age 1 and older with moderate or severe renal impairment (eGFR less than 50 mL/min/1.73 m2). Refer to the manufacturer's instructions for renal impairment in children less than age 1 and for recommendations for switching to and from other anticoagulants.Released: March 2022Nursing Drug Handbook© 2022 Wolters KluwersecukinumabCosentyxPharmaceutical company: NovartisNEW INDICATION & DOSAGEActive psoriatic arthritisChildren age 2 and older, weighing more than 50 kg: 150 mg subcut at weeks 0, 1, 2, 3, and 4; then 150 mg every 4 weeks thereafter.Children age 2 and older, weighing 15 to less than 50 kg: 75 mg subcut at weeks 0, 1, 2, 3, and 4; then 75 mg every 4 weeks thereafter.Active enthesitis-related arthritisChildren age 4 and older, weighing more than 50 kg: 150 mg subcut at weeks 0, 1, 2, 3, and 4; then 150 mg every 4 weeks thereafter.Children age 4 and older, weighing 15 to less than 50 kg: 75 mg subcut at weeks 0, 1, 2, 3, and 4; then 75 mg every 4 weeks thereafter.Released: March 2022Nursing Drug Handbook© 2022 Wolters KluwerupadacitinibRinvoqPharmaceutical company: AbbVie Inc.NEW INDICATION & DOSAGEPsoriatic arthritis in patients with inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockersAdults: 15 mg PO once daily.Adjust-a-dose: If serious infection develops, interrupt the drug until infection is controlled. Interrupt therapy if ANC is less than 1,000 cells/mm3 or absolute lymphocyte count (ALC) is less than 500 cells/mm3 or Hb level is less than 8 g/dL. Restart the drug once ANC, ALC, or Hb levels return to above these values. If hepatic transaminase levels rise and drug-induced liver injury is suspected, interrupt therapy.Refractory, moderate to severe atopic dermatitis not adequately controlled with other systemic drugs, including biologics, or when use of those therapies is inadvisableAdults and children age 12 and older weighing at least 40 kg: Initially, 15 mg PO once daily. May increase to 30 mg once daily. If adequate response isn't achieved with 30-mg dose, stop therapy. Use lowest effective dose needed to maintain response.Adjust-a-dose: In older adults or patients with severe renal impairment (creatinine clearance less than 30 mL/minute), give 15 mg once daily. If used concomitantly with strong CYP3A4 inhibitors, give 15 mg once daily. Not recommended for patients with severe hepatic impairment.Released: March 2022Nursing Drug Handbook© 2022 Wolters KluwervoxelotorOxbrytaPharmaceutical company: Global Blood TherapeuticsNEW AVAILABLE FORMTablet for suspension: 300 mgINDICATION & DOSAGESickle cell diseaseChildren age 4 to less than 12, weighing 40 kg or more: 1,500 mg PO once daily, with or without hydroxyurea.Children age 4 to less than 12, weighing 20 to less than 40 kg: 900 mg PO once daily, with or without hydroxyurea.Children age 4 to less than 12, weighing 10 to less than 20 kg: 600 mg PO once daily, with or without hydroxyurea.Adjust-a-dose: For children age 4 to less than 12 with severe hepatic impairment (Child-Pugh class C) reduce dose based on body weight. If 40 kg or more, give 1,000 mg (two 500-mg tablets) or 900 mg (three 300-mg tablets for oral suspension) daily; if 20 to less than 40 kg, give 600 mg daily; if 10 to less than 20 kg, give 300 mg daily. For children age 4 to less than 12 who are currently receiving a strong or moderate CYP3A4 inducer, see the manufacturer's instructions for dosage adjustment based on weight.Released: March 2022Nursing Drug Handbook© 2022 Wolters Kluwer
New Drug Indications - February 2022
abataceptOrenciaPharmaceutical company: Bristol-Myers SquibbNEW INDICATION & DOSAGEProphylaxis of acute graft-versus-host disease, in combination with a calcineurin inhibitor and methotrexate, in patients undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donorAdults and children age 6 and older: 10 mg/kg dose (maximum dose 1,000 mg) IV infusion over 60 minutes on the day before transplantation, followed by a dose on days 5, 14, and 28 after transplant.Children ages 2 to less than 6: 15 mg/kg dose IV infusion over 60 minutes on the day before transplantation, followed by 12 mg/kg on days 5, 14, and 28 after transplant.Released: February 2022Nursing Drug Handbook© 2022 Wolters KluwerbudesonideTarpeyoPharmaceutical company: Calliditas TherapeuticsNEW AVAILABLE FORMDelayed-release capsules: 4 mgINDICATION & DOSAGEProteinuria in patients with primary immunoglobulin A nephropathy at risk for rapid disease progressionAdults: 16 mg PO daily in the morning at least 1 hour before a meal.Adjust-a-dose: Reduce dose to 8 mg daily for 2 weeks before discontinuing the drug.Released: February 2022Nursing Drug Handbook© 2022 Wolters KluwercarfilzomibKyprolisPharmaceutical company: Amgen, Inc.NEW INDICATION & DOSAGERelapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj and dexamethasone after one to three prior lines of therapyAdults: For twice-weekly 20/56 mg/m2 regimen, give as a 30-minute IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle in combination with subcut daratumumab and hyaluronidase-fihj, and dexamethasone until disease progression or unacceptable toxicity occurs. Initially, give 20 mg/m2 on cycle 1, days 1 and 2. If tolerated, escalate to 56 mg/m2 on cycle 1, day 8 and thereafter. Give dexamethasone 30 minutes to 4 hours before carfilzomib and 1 to 3 hours before IV daratumumab and hyaluronidase-fihj.For once-weekly 20/70 mg/m2 regimen, give as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day cycle in combination with subcut daratumumab and hyaluronidase-fihj, and dexamethasone until disease progression or unacceptable toxicity occurs. Initially, give 20 mg/m2 on cycle 1, day 1. If tolerated, escalate to 70 mg/m2 on cycle 1, day 8 and thereafter. Give dexamethasone 30 minutes to 4 hours before carfilzomib and 1 to 3 hours before IV daratumumab and hyaluronidase-fihj.Adjust-a-dose: Refer to the manufacturer's instructions for daratumumab and hyaluronidase-fihj for dosage information.Released: February 2022Nursing Drug Handbook© 2022 Wolters Kluwerclindamycin phosphateXaciatoPharmaceutical company: Daré BiosciencesNEW FORMULATIONGel: 2%INDICATION & DOSAGEBacterial vaginosisAdults and children age 12 and older: 1 applicatorful vaginally as a single dose.Released: February 2022Nursing Drug Handbook© 2022 Wolters Kluwerelbasvir–grazoprevirZepatierPharmaceutical company: Merck Sharp & Dohme CorpNEW INDICATION & DOSAGEChronic hepatitis C virus (HCV) genotypes 1 or 4 infection, with or without ribavirinChildren age 12 and older or weighing at least 30 kg: 1 tablet PO once daily. See manufacturer's instructions for recommended dosing regimens and durations for treatment of HCV genotype 1 or 4 in patients with or without cirrhosis.Adjust-a-dose: If ALT level is greater than 10 times the upper limit of normal, consider discontinuing the drug. If ALT level is elevated and accompanied by signs or symptoms of liver inflammation, increased conjugated bilirubin or alkaline phophatase level, or increased INR, discontinue the drug. If creatinine clearance is 50 mL/minute or less and ribavirin is used, refer to ribavirin prescribing information for ribavirin dose adjustment.Released: February 2022Nursing Drug Handbook© 2022 Wolters KluwerpembrolizumabKeytrudaPharmaceutical company: Merck & Co.NEW INDICATION & DOSAGEAdjuvant treatment of melanoma with lymph node involvement after complete resectionChildren age 12 and older: 2 mg/kg IV over 30 minutes every 3 weeks up to maximum dose of 200 mg. Continue until disease recurrence or unacceptable toxicity occurs, or up to 12 months in patients without disease recurrence.Released: February 2022Nursing Drug Handbook© 2022 Wolters KluwerrituximabRituxanPharmaceutical company: GenentechNEW INDICATION & DOSAGEPreviously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia in combination with chemotherapyChildren age 6 months and older: 375 mg/m2 IV infusion in combination with systemic Lymphome Malin B chemotherapy. Give the drug on day 2 and day 1 (48 hours apart) of each of the induction courses, and on day 1 of each of the two consolidation courses. Give prednisone component of regimen before rituximab. Refer to the manufacturer's instructions for additional dosing information.Released: February 2022Nursing Drug Handbook© 2022 Wolters KluwertofacitinibXeljanz and Xeljanz XRPharmaceutical company: PfizerNEW INDICATION & DOSAGEAnkylosing spondylitis after inadequate response or intolerance to one or more tumor necrosis factor blockersAdults: 5 mg (immediate-release) PO twice daily. Or, 11 mg (extended-release) PO once daily.Adjust-a-dose: Reduce dosage to 5 mg (immediate-release) PO daily in patients with moderate to severe renal impairment or moderate hepatic impairment in those receiving concurrent potent CYP3A4 inhibitors, and in those receiving a moderate CYP3A4 inhibitor with a strong CYP2C19 inhibitor.Released: February 2022Nursing Drug Handbook© 2022 Wolters Kluwer
New Drug Indications - January 2022
bictegravir–emtricitabine–tenofovir alafenamideBiktarvyPharmaceutical company: Gilead SciencesNEW AVAILABLE FORMTablets: 30 mg bictegravir; 120 mg emtricitabine; 15 mg tenofovir alafenamideNEW INDICATION & DOSAGEHIV-1 infection in children weighing 14 to less than 25 kg who have no antiretroviral treatment history, or to replace current antiretroviral regimen in children who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to individual componentsChildren weighing 14 to less than 25 kg: 1 tablet of 30 mg bictegravir; 120 mg emtricitabine; 15 mg tenofovir alafenamide PO daily.Released: January 2022Nursing Drug Handbook© 2022 Wolters KluwerdupilumabDupixentPharmaceutical company: Sanofi and Regeneron PharmaceuticalsNEW INDICATION & DOSAGEAdd-on maintenance treatment of moderate to severe eosinophilic or oral corticosteroid-dependent asthmaChildren ages 6 to 11 weighing 30 kg or more: 200 mg subcut every other week.Children ages 6 to 11 weighing 15 to less than 30 mg: 100 mg subcut every other week or 300 mg every 4 weeks.Released: January 2022Nursing Drug Handbook© 2022 Wolters Kluwerferric carboxymaltoseInjectaferPharmaceutical company: Daiichi SankyoNEW INDICATION & DOSAGEIron deficiency anemia in patients intolerant to or who have had unsatisfactory response to oral ironChildren age 1 and older weighing 50 kg or more: 750 mg IV on day 1; repeat dose after at least 7 days. May repeat course of therapy if anemia recurs. Maximum cumulative dose is 1,500 mg per course.Children age 1 and older weighing less than 50 kg: 15 mg/kg IV on day 1; repeat dose after at least 7 days. May repeat course of therapy if anemia recurs.Released: January 2022Nursing Drug Handbook© 2022 Wolters KluwerlacosamideVimpatPharmaceutical company: UCB, Inc.NEW INDICATION & DOSAGEMonotherapy for partial-onset seizuresChildren age 1 month and older weighing 6 to less than 11 kg: Initially, 1 mg/kg PO or IV b.i.d. Then increase by 1 mg/kg b.i.d. at weekly intervals to recommended dose of 3 to 6 mg/kg b.i.d.Children age 1 month and older weighing less than 6 kg: Initially, 0.66 mg/kg IV t.i.d. Then increase by 0.66 mg/kg IV t.i.d. at weekly intervals to recommended IV dose of 2.5 to 5 mg/kg t.i.d. Or initially, 1 mg/kg PO b.i.d. Then increase by 1 mg/kg b.i.d. at weekly intervals to recommended PO dose of 3.75 to 7.5 mg/kg b.i.d.Released: January 2022Nursing Drug Handbook© 2022 Wolters Kluwerpilocarpine hydrochloride (ophthalmic)VuityPharmaceutical company: AllerganNEW AVAILABLE FORMOphthalmic solution: 1.25%INDICATION & DOSAGEPresbyopia (Vuity)Adults: Instill 1 drop of 1.25% solution in each eye once daily.Released: January 2022Nursing Drug Handbook© 2022 Wolters Kluwer
New Drug Indications - December 2021
abemaciclibVerzenioPharmaceutical company: Eli Lilly and CompanyNEW INDICATION & DOSAGEAdjuvant treatment for hormone receptor-positive, HER2-negative, node-positive, early breast cancer, in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), in patients at high risk of recurrence and with a Ki-67 score of 20% or more as determined by an FDA-approved testAdults: 150 mg PO b.i.d. until completion of 2 years of treatment or until disease recurrence or unacceptable toxicity occurs.Released: December 2021Nursing Drug Handbook© 2021 Wolters KluweratezolizumabTecentriqPharmaceutical company: GenentechNEW INDICATION & DOSAGEAdjuvant treatment after resection and platinum-based chemotherapy for patients with stage II to IIIA non–small-cell lung cancer whose tumors express PD-L1, as determined by an FDA-approved testAdults: 840-mg IV infusion every 2 weeks; or 1,200 mg every 3 weeks; or 1,680 mg every 4 weeks until disease recurrence or unacceptable toxicity occurs, or up to 1 year.Released: December 2021Nursing Drug Handbook© 2021 Wolters KluwercetuximabErbituxPharmaceutical company: Eli Lilly and CompanyNEW INDICATION & DOSAGEMetastatic colorectal cancer with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy, in combination with encorafenibAdults: Initially, 400 mg/m2 IV infusion over 120 minutes, then 250 mg/m2 IV infusion over 60 minutes weekly with encorafenib 300 mg PO daily until disease progression or unacceptable toxicity occurs. Refer to encorafenib prescribing information.Released: December 2021Nursing Drug Handbook© 2021 Wolters Kluwerdexamethasone ophthalmic insertDextenzaPharmaceutical company: Ocular TherapeutixNEW FORMULATIONOphthalmic insert:0.4 mgINDICATION & DOSAGEOcular itching associated with allergic conjunctivitisAdults: Place a single 0.4-mg insert into lower lacrimal canaliculus.Released: December 2021Nursing Drug Handbook© 2021 Wolters KluwerevolocumabRepathaPharmaceutical company: AmgenINDICATION & DOSAGEAdjunct to diet and other LDL-lowering therapies to reduce LDL cholesterol in children with heterozygous familial hypercholesterolemiaChildren age 10 and older: 140 mg subcut every 2 weeks or 420 mg subcut once monthly. When switching dosage regimens, give first dose of new regimen on next scheduled date of prior regimen.Adjunct to other LDL-lowering therapies for homozygous familial hypercholesterolemia in those who require additional lowering of LDL cholesterolAdults and children age 10 and older: 420 mg subcut once monthly. May increase dose to 420 mg every 2 weeks if clinically meaningful response isn't achieved in 12 weeks. Patients on lipid apheresis may initiate treatment with 420 mg every 2 weeks given after apheresis session is complete.Released: December 2021Nursing Drug Handbook© 2021 Wolters KluwerpembrolizumabKeytrudaPharmaceutical company: Merck Sharp & DohmeINDICATION & DOSAGEPersistent, recurrent, or metastatic cervical cancer in patients whose tumors express PD-L1, as determined by an FDA-approved test, in combination with chemotherapy, with or without bevacizumabAdults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in patients without disease progression. Give before chemotherapy with or without bevacizumab when given the same day.Released: December 2021Nursing Drug Handbook© 2021 Wolters Kluwer
New Drug Indications - November 2021
brivaracetamBriviactPharmaceutical company: UCB, Inc.NEW INDICATION & DOSAGEAdjunctive therapy or monotherapy for partial-onset seizures in patients with epilepsyChildren age 1 month and older weighing 20 to less than 50 kg: 0.5 to 1 mg/kg PO b.i.d. Adjust dosage based on clinical response and tolerability. Minimum dose, 0.5 mg/kg b.i.d.; maximum dose, 2 mg/kg b.i.d.Children age 1 month and older weighing 11 to less than 20 kg: 0.5 to 1.25 mg/kg PO b.i.d. Adjust dosage based on clinical response and tolerability. Minimum dose, 0.5 mg/kg b.i.d.; maximum dose, 2.5 mg/kg b.i.d.Children age 1 month and older weighing less than 11 kg: 0.75 mg/kg to 1.5 mg/kg PO b.i.d. Adjust dosage based on clinical response and tolerability. Minimum dose, 0.75 mg/kg b.i.d.; maximum dose, 3 mg/kg b.i.d.Released: November 2021Nursing Drug Handbook© 2021 Wolters Kluwer  cabozantinibCabometyxPharmaceutical company: Exelixis, Inc.NEW INDICATION & DOSAGELocally advanced or metastatic differentiated thyroid cancer that has progressed following prior VEGFR-targeted therapy in those who are radioactive iodine-refractory or ineligible (Cabometyx only)Adults and children age 12 and older with BSA of 1.2 m2 or more: 60 mg PO daily until disease progression or unacceptable toxicity occurs.Adjust-a-dose: Reduce starting dose to 40 mg PO once daily for patients with moderate hepatic impairment (Child-Pugh class B). Refer to the manufacturer's instructions for toxicity-related dosage adjustments and for use with strong CYP3A4 inducers or inhibitors.Children age 12 and older with BSA less than 1.2 m2: 40 mg PO daily until disease progression or unacceptable toxicity occurs.Adjust-a-dose: Reduce starting dose to 20 mg PO once daily for patients with moderate hepatic impairment (Child-Pugh class B). Refer to the manufacturer's instructions for toxicity-related dosage adjustments and for use with strong CYP3A4 inducers or inhibitors.Released: November 2021Nursing Drug Handbook© 2021 Wolters Kluwer  paliperidone palmitateInvega HafyeraPharmaceutical company: JanssenNEW AVAILABLE FORMInjection: 1,092 mg/3.5 mL; 1,560 mg/5 mL single-dose, prefilled syringesNEW INDICATION & DOSAGESchizophreniaAdults: Use 6-month IM paliperidone (Invega Hafyera) only after monthly IM paliperidone (Invega Sustenna) has been established as adequate treatment for at least 4 months and at the same dosage for at least 2 months, or after IM paliperidone (Invega Trinza) has been established as adequate treatment for at least a one 3-month cycle. Initiate when the next once-a-month injection is scheduled, or up to 1 week before or after. Initiate when the next every-3-month injection is scheduled, or up to 2 weeks before or after. Dosage is based on dosage of previous product. If last dose of once-a-month product was 156 mg, give 1,092 mg of 6-month product; if last dose of once-a-month product was 234 mg, give 1,560 mg of 6-month product. If last dose of 3-month product was 546 mg, give 1,092 mg of 6-month product; if last dose of 3-month product was 819 mg, give 1,560 mg of 6-month product. Because of long-acting nature of Invega Hafyera, patient's response to adjusted dose may not be apparent for several months. See the manufacturer's instructions for missed dosage schedules.Released: November 2021Nursing Drug Handbook© 2021 Wolters Kluwer  ruxolitinibJakafiPharmaceutical company: IncyteNEW INDICATION & DOSAGEChronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapyAdults and children age 12 and older: 10 mg PO b.i.d.Adjust-a-dose: Recommended starting dose is 5 mg b.i.d. in patients with moderate to severe renal impairment (creatinine clearance of 15 to 59 mL/min) or when given concomitantly with fluconazole 200 mg or less. Starting dose for patients with end-stage-renal disease on dialysis is 10 mg after dialysis session. After 6 months of treatment in patients who have discontinued corticosteroids, taper the drug by one dose level every 8 weeks (10 mg b.i.d. to 5 mg b.i.d. to 5 mg once daily). Consider retreatment if acute GVHD recurs during or after taper. Refer to the manufacturer's instructions for toxicity-related dosage adjustments.Released: November 2021Nursing Drug Handbook© 2021 Wolters Kluwer  zanubrutinibBrukinsaPharmaceutical company: BeiGeneNEW INDICATION & DOSAGEWaldenström macroglobulinemiaAdults: 160 mg PO b.i.d. or 320 mg PO once daily until disease progression or unacceptable toxicity occurs.Adjust-a-dose: For patients with severe hepatic impairment (Child-Pugh class C), reduce dose to 80 mg PO b.i.d. If given with strong CYP3A inhibitor, reduce dose to 80 mg PO once daily. If given with moderate CYP3A inhibitor, reduce dose to 80 mg PO b.i.d. After stopping CYP3A inhibitor, resume previous zanubrutinib dose. Refer to the manufacturer's instructions for toxicity-related dosage adjustments.Relapsed or refractory marginal zone lymphoma in patients who have received at least one anti-CD20-based regimenAdults: 160 mg PO b.i.d. or 320 mg PO once daily, until disease progression or unacceptable toxicity occurs.Adjust-a-dose: For patients with severe hepatic impairment (Child-Pugh class C), reduce dose to 80 mg PO b.i.d. If given with strong CYP3A inhibitor, reduce dose to 80 mg PO once daily. If given with moderate CYP3A inhibitor, reduce dose to 80 mg PO b.i.d. After stopping CYP3A inhibitor, resume previous zanubrutinib dose. Refer to the manufacturer's instructions for toxicity-related dosage adjustments.Released: November 2021Nursing Drug Handbook© 2021 Wolters Kluwer
New Drug Indications - October 2021
dalbavancinDalvancePharmaceutical company: AllerganNEW INDICATION & DOSAGEAcute bacterial skin and skin-structure infections caused by susceptible strains of gram-positive microorganisms (Staphylococcus aureus [including MRSA], Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group [S. anginosus,S. intermedius, S. constellatus], Enterococcus faecalis (vancomycin-susceptible strains)Children age 6 to less than 18: 18 mg/kg IV infusion as a single dose, up to a maximum of 1,500 mg.Children from birth to less than age 6: 22.5 mg/kg IV infusion as a single dose, up to a maximum of 1,500 mg.Adjust-a-dose: Dose adjustment for children with creatinine clearance less than 30 mL/minute has not been established.Released: October 2021Nursing Drug Handbook© 2021 Wolters KluwerempagliflozinJardiancePharmaceutical company: Boehringer Ingelheim and Eli LillyNEW INDICATION & DOSAGETo reduce the risk of CV death or hospitalization for heart failure in patients with heart failure and reduced ejection fractionAdults: 10 mg PO daily in the morning.CONTRAINDICATIONS & CAUTIONSNot recommended for glycemic control in patients with eGFR less than 30 mL/min/1.73 m2.Dosing recommendations have not been determined for patients with type 2 diabetes and established CV disease with eGFR less than 30 mL/min/1.73 m2, or who have heart failure with reduced ejection fraction with eGFR less than 20 mL/min/1.73 m2.Released: October 2021Nursing Drug Handbook© 2021 Wolters Kluwerimmune globulin IV (human)OctagamPharmaceutical company: OctapharmaNEW INDICATION & DOSAGEDermatomyositis (Octagam 10%)Adults: 2 g/kg divided in equal doses given over 2 to 5 consecutive days every 4 weeks. Initial infusion rate is 0.01 mL/kg/min (1 mg/kg/min) for the first 30 minutes. If tolerated, the rate may be gradually increased to 0.02 mL/kg/min (2 mg/kg/min) and, if tolerated, may gradually increase to a maximum of 0.04 mL/kg/min (4 mg/kg/min).Alert: Patients with dermatomyositis are at increased risk for thromboembolic events; do not exceed infusion rate of 0.04 mL/kg/min.Released: October 2021Nursing Drug Handbook© 2021 Wolters KluwerivosidenibTibsovoPharmaceutical company: Servier PharmaceuticalsNEW INDICATION & DOSAGELocally advanced or metastatic cholangiocarcinoma with IDH1 mutation as detected by an FDA-approved test in patients who have been previously treatedAdults: 500 mg PO daily until disease progression or unacceptable toxicity occurs.Released: October 2021Nursing Drug Handbook© 2021 Wolters KluwerlenvatinibLenvimaPharmaceutical company: Eisai, Inc.NEW INDICATION & DOSAGEAdvanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient in patients who have disease progression after systemic therapy in any setting and who are not candidates for curative surgery or radiation, in combination with pembrolizumabAdults: 20 mg PO once daily until disease progression or unacceptable toxicity occurs. Give with pembrolizumab according to the manufacturer's prescribing information.Released: October 2021Nursing Drug Handbook© 2021 Wolters KluwermepolizumabNucalaPharmaceutical company: GlaxoSmithKlineNEW INDICATION & DOSAGEMaintenance treatment of chronic rhinosinusitis with nasal polyps in patients with inadequate response to nasal corticosteroidsAdults: 100 mg subcut once every 4 weeks into upper arm, thigh, or abdomen.Released: October 2021Nursing Drug Handbook© 2021 Wolters KluwernivolumabOpdivoPharmaceutical company: Bristol Myers SquibbNEW INDICATION & DOSAGEAdjuvant treatment of urothelial carcinoma in patients who are at high risk for recurrence after undergoing radical resectionAdults: 240-mg IV infusion every 2 weeks, or 480-mg IV infusion every 4 weeks, until disease recurrence or unacceptable toxicity occurs, or up to 1 year of treatment.Released: October 2021Nursing Drug Handbook© 2021 Wolters KluwerpembrolizumabKeytrudaPharmaceutical company: Merck Sharp & DohmeNEW INDICATION & DOSAGEAdvanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient in patients who have disease progression after systemic therapy in any setting and who are not candidates for curative surgery or radiation, in combination with lenvatinibAdults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in patients without disease progression. Give with lenvatinib according to the manufacturer's prescribing information.High-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single-agent adjuvant treatment after surgeryAdults: Neoadjuvant treatment in combination with chemotherapy for 24 weeks (8 doses of 200-mg IV infusion every 3 weeks, or 4 doses of 400-mg IV infusion every 6 weeks), followed by adjuvant treatment as a single agent for up to 27 weeks (9 doses of 200-mg IV infusion every 3 weeks, or 5 doses of 400-mg IV infusion every 6 weeks) or until disease progression or unacceptable toxicity occurs. Give prior to chemotherapy when given on the same day.Locally recurrent unresectable or metastatic TNBC in patients whose tumors express PD-L1 as determined by an FDA-approved test, in combination with chemotherapyAdults: 200 mg every 3 weeks or 400 mg every 6 weeks, until disease progression or unacceptable toxicity occurs or up to 24 months in patients without disease progression. Give prior to chemotherapy when given on the same day.Released: October 2021Nursing Drug Handbook© 2021 Wolters KluwerrivaroxabanXareltoPharmaceutical company: JanssenNEW INDICATION & DOSAGETo reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD, once hemostasis is establishedAdults: 2.5 mg PO b.i.d., in combination with aspirin (75 to 100 mg) once daily.Released: October 2021Nursing Drug Handbook© 2021 Wolters Kluwer
New Drug Indications - September 2021
deferiproneFerriproxPharmaceutical company: Chiesi USANEW AVAILABLE FORMSOral solution: 80 mg/mLTablets: 1,000 mg for t.i.d. dosing; 1,000 mg for b.i.d. dosingINDICATION & DOSAGETreatment of transfusional iron overload in patients with thalassemia syndromesAdults and children age 8 and older: Initially, 25 mg/kg tablets or oral solution PO t.i.d., or 25 mg/kg tablets PO b.i.d., for a total of 75 mg/kg/day. May titrate to maximum dosage of 99 mg/kg/day based on patient response and therapeutic goals. Round dose to nearest 500 mg (one-half 1,000-mg tablet), 250 mg (one-half 500-mg tablet) or 2.5 mL of oral solution. Children age 3 and older: Initially, 25 mg/kg oral solution PO t.i.d., for a total of 75 mg/kg/day. May titrate to maximum dosage of 99 mg/kg/day based on patient response and therapeutic goals. Round dose to nearest 2.5 mL of oral solution. Treatment of transfusional iron overload in patients with sickle cell disease or other anemiasAdults and children age 8 and older: Initially, 25 mg/kg tablets or oral solution PO t.i.d., or 25 mg/kg tablets PO b.i.d., for a total of 75 mg/kg/day. May titrate to maximum dosage of 99 mg/kg/day based on patient response and therapeutic goals. Round dose to nearest 500 mg (one-half 1,000-mg tablet), 250 mg (one-half 500-mg tablet) or 2.5 mL of oral solution. Children age 3 and older: Initially, 25 mg/kg oral solution PO t.i.d., for a total of 75 mg/kg/day. May titrate to maximum dosage of 99 mg/kg/day based on patient response and therapeutic goals. Round dose to nearest 2.5 mL of oral solution. Adjust-a-dose (for both indications): To minimize GI upset when initiating therapy, may start at 45 mg/kg/day and increase weekly by 15 mg/kg/day. If serum ferritin level falls consistently below 500 mcg/L, consider temporary therapy interruption. For ANC less than 1,500/mm3, interrupt therapy immediately and monitor until recovery; do not rechallenge unless the potential benefit outweighs the risk. For ANC less than 500/mm3, consider hospitalization and other clinically appropriate management; do not resume unless potential benefits outweigh the risks.Released: September 2021Nursing Drug Handbook© 2021 Wolters KluwerposaconazoleNoxafilPharmaceutical company: Merck Sharp & DohmeNEW INDICATION & DOSAGETreatment of invasive aspergillosisAdults and children ages 13 to 17: 300-mg delayed-release tablet PO b.i.d. on first day, then 300 mg PO once daily. Or, 300 mg IV b.i.d. on first day, then 300 mg IV once daily for 6 to 12 weeks. May switch between IV and delayed-release tablets; no loading dose is required when switching between formulations.Released: September 2021Nursing Drug Handbook© 2021 Wolters KluwersecnidazoleSolosecPharmaceutical company: Lupin PharmaceuticalsNEW INDICATION & DOSAGETreatment of trichomoniasisAdults: One single dose of 2 g PO. Treat sexual partners at same dose at same time.Released: September 2021Nursing Drug Handbook© 2021 Wolters KluwersugammadexBridionPharmaceutical company: Merck Sharp & DohmeNEW INDICATION & DOSAGEReversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in patients undergoing surgeryChildren age 2 and older (routine reversal of rocuronium and vecuronium-induced neuromuscular blockade): Base doses and timing of drug administration on twitch responses and extent of spontaneous recovery. Give 4 mg/kg IV bolus over 10 seconds if recovery of twitch response has reached one to two posttetanic counts and there are no twitch responses to train-of-four (TOF) stimulation. Give 2 mg/kg IV bolus over 10 seconds if spontaneous recovery has reached the reappearance of the second twitch in response to TOF stimulation.Alert: Immediate reversal of rocuronium-only induced neuromuscular blockade has not been studied in children.Released: September 2021Nursing Drug Handbook© 2021 Wolters Kluwer
 |<  <  1 - 2 - 3 - 4 - 5 - 6  >  >| 
Displaying results 37-45 (of 49)

CE Resources

Nursing Resources

About NursingCenter

 

© 2025 Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved. – Terms & Conditions – Privacy Policy – Disclaimer – Your California Privacy Choices -- v10.03.00